Multiscale Anti-TNF Drugs Simulations

an on-line supplement for

Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability

[ Kirschner Lab Time-Lapse Simulations Homepage ]




Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE, Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability and not apoptotic and cytolytic activities, J. Immunology, 2012, The Journal of Immunology, April 1, vol. 188, no. 7, pp. 3169-3178, DOI: 10.4049/jimmunol.1103298, PMID: 22379032, PMCID: 3311778

Supplemental Information - Supplement1





Movie 1

Movie 2
Control of Mtb infection within a
well-circumscribed granuloma in
the absence of TNF inhibitor

Infection dynamics after granuloma treatment
with etanercept at a small vascular
permeability coefficient (kc = 1.1×10-8 cm/s)

Movie 3

Movie 4
Infection dynamics after granuloma treatment
with etanercept at a high vascular
permeability coefficient (kc = 1.1×10-7 cm/s)

Infection dynamics after granuloma treatment
with infliximab at a small vascular
permeability coefficient (kc = 1.1×10-8 cm/s)

Movie 5

Movie 6
Infection dynamics after granuloma treatment
with infliximab at a high vascular
permeability coefficient (kc = 1.1×10-7 cm/s)

The effect of pharmacokinetic fluctuations in
the blood concentration of infliximab
on infection dynamics for a small vascular
permeability coefficient (kc = 1.1×10-8 cm/s)

Movie 7
The effect of pharmacokinetic fluctuations in the
blood concentration of infliximab on infection
dynamics for a high vascular permeability
coefficient (kc = 1.1×10-7 cm/s)




[ Kirschner Lab Time-Lapse Simulations Homepage ]